Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Details) - Segments Information

v3.19.2
SEGMENT INFORMATION (Details) - Segments Information - USD ($)
 3 Months Ended 9 Months Ended
Jul. 31, 2019
Jul. 31, 2018
Jul. 31, 2019
Jul. 31, 2018
Oct. 31, 2018
Net loss:          
Net Loss $ (2,166,048) $ (5,593,576) $ (9,707,591) $ (8,851,564)  
Operating costs and expenses excluding non-cash share based compensation expense:          
Operating costs and expenses 1,353,514 1,339,971 5,108,862 4,766,828  
Plus non-cash share-based compensation expense 830,898 4,628,333 4,902,512 5,227,016  
Total operating costs and expenses 2,184,412 5,968,304 10,011,374 9,993,844  
Total assets:          
Total Assets 6,842,706   6,842,706   $ 6,448,542
Operating Segments [Member] | Cancer Diagnostics [Member]          
Net loss:          
Net Loss (917,363) (2,359,568) (4,024,785) (3,783,854)  
Operating costs and expenses excluding non-cash share based compensation expense:          
Operating costs and expenses 507,356 569,512 1,953,760 1,692,865  
Total assets:          
Total Assets 3,201,233   3,201,233   2,545,803
Operating Segments [Member] | Cancer Therapeutics [Member]          
Net loss:          
Net Loss (1,203,468) (2,901,708) (4,807,668) (4,583,070)  
Operating costs and expenses excluding non-cash share based compensation expense:          
Operating costs and expenses 801,704 359,006 2,084,694 1,807,515  
Total assets:          
Total Assets 3,279,496   3,279,496   2,157,359
Operating Segments [Member] | Patent Licensing [Member]          
Net loss:          
Net Loss (45,217) (332,300) (875,138) (484,640)  
Operating costs and expenses excluding non-cash share based compensation expense:          
Operating costs and expenses 44,454 $ 411,453 1,070,408 $ 1,266,448  
Total assets:          
Total Assets $ 361,977   $ 361,977   $ 1,745,380